← Back to Clinical Trials
Recruiting NCT06867198

NCT06867198 Peanuts for Cardiometabolic, Brain, and Intestinal Health

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06867198
Status Recruiting
Phase
Sponsor Georgia State University
Condition Prediabetes
Study Type INTERVENTIONAL
Enrollment 72 participants
Start Date 2025-03-06
Primary Completion 2027-09

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 59 Years
Study Type INTERVENTIONAL
Interventions
Peanuts

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 72 participants in total. It began in 2025-03-06 with a primary completion date of 2027-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overall objective of this 14-month randomized crossover study is to seek evidence demonstrating that daily consumption of peanuts and peanut products improve cardiometabolic, cognitive, and intestinal health in a racially diverse prediabetes population.

Eligibility Criteria

Inclusion Criteria: * men and women * 20-59 years of age * BMI: 24.5 - 35.5 kg/m\^2 * Prediabetes (fasting blood glucose levels 100-125 mg/dL and/or HbA1c between 5.7-6.4%) * Ability to give consent Exclusion Criteria: * Allergies to peanuts and peanut products * Use of insulin, antidiabetic, antibiotics, and anti-inflammatory drugs * Active cancer, gastrointestinal, renal, cardiovascular, thyroid, and neurological diseases or severe head injury * Smoking * Consumes greater than 2 alcoholic beverages per day * Consumes antioxidant, probiotic, and prebiotic supplements * Pregnant or Lactating * Actively participating in a weight loss program MRI Exclusion Criteria: * Certain neurological disorders (e.g., uncontrolled seizure disorders) * Braces on their teeth, a cardiac pacemaker; hearing aid; other metal in the body or eyes (which may include certain metallic-embedded tattoos), including but not limited to pins, screws, shrapnel, plates, dentures or other metal objects

Contact & Investigator

Central Contact

Rafaela G Feresin, PhD

✉ peanuts@gsu.edu

📞 404-413-1233

Principal Investigator

Rafaela G Feresin, PhD

PRINCIPAL INVESTIGATOR

Georgia State University

Frequently Asked Questions

Who can join the NCT06867198 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 59 Years, studying Prediabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06867198 currently recruiting?

Yes, NCT06867198 is actively recruiting participants. Contact the research team at peanuts@gsu.edu for enrollment information.

Where is the NCT06867198 trial being conducted?

This trial is being conducted at Atlanta, United States.

Who is sponsoring the NCT06867198 clinical trial?

NCT06867198 is sponsored by Georgia State University. The principal investigator is Rafaela G Feresin, PhD at Georgia State University. The trial plans to enroll 72 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology